<DOC>
	<DOCNO>NCT02247375</DOCNO>
	<brief_summary>Safety , pharmacokinetics , pharmacodynamics [ CD11b/CD18 ( Mac-1 ) expression ] efficacy .</brief_summary>
	<brief_title>Pharmacokinetics , Safety Efficacy BIIL 284 BS Patients With Rheumatoid Arthritis ( RA )</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>Male female 18 65 year age Patients suffer active rheumatoid arthritis define ARA criterion revise 1987 At least 4 follow 7 criterion must present : morning stiffness around joint last least 1 hour maximal improvement least 6 week arthritis ( soft tissue thicken fluid bony overgrowth alone ) least 3 joint area least 6 week arthritis hand joint ( least one area swell wrist , metacarpophalangeal ( MCP ) proximal interphalangeal ( PIP ) joint ) least 6 week symmetric arthritis ( observed physician ) simultaneous involvement joint side body least 6 week rheumatoid nodule ( observed physician ) bony prominence extensor surface juxtaarticular region serum rheumatoid factor positive xray change typical rheumatoid arthritis ( erosion unequivocal bony decalcification localise marked adjacent involved joint ) Patient belong RA functional class I , II III Patient 's write informed consent Pregnancy ( excluded pregnancy test ) breast feed Women childbearing potential use adequate contraception Treatment methotrexate previous month intend use trial period Treatment slow act antirheumatic drug ( SAARDs ) /diseasemodifying antirheumatic drug ( DMARDs ) parenteral gold , Dpenicillamine , sulfasalazine , chloroquine / hydroxychloroquine corticosteroid last 2 month prior study entry Treatment one SAARD/DMARD and/or corticosteroid last 2 month prior study entry Change treatment SAARDs/DMARDs last 2 month prior study entry intend change trial duration Change treatment corticosteroid last month prior study entry intend change trial duration Systemic treatment corticosteroid dose high 10 mg/day 0.2 mg/kg/day ( prednisone equivalent ) , respectively ( whichever low ) last month prior study entry intend use trial treatment period Change treatment nonsteroidal antiinflammatory drug ( NSAIDs ) last month prior study entry intend change trial duration Treatment EnbrelTM ( etanercept ) experimental therapy last 3 month prior study entry Synovectomy and/or surgical treatment RA previous month trial Clinical evidence know severe cardiovascular , hepatic , renal , respiratory , metabolic , haematological , immunological , gastrointestinal , hormonal mental disorder Any rheumatological nonrheumatological disease could interfere evaluation efficacy safety Patients active malignant disease Patients chronic acute infection previous month Patients abnormal , clinically relevant laboratory value relate RA Participation another clinical trial study previous month Previous participation trial ( i.e . allocate randomized treatment number ) Patient unable comply protocol Patient know drug abuse Patient know alcohol abuse</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>